Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal protein.
作者信息
Andrikopoulou Angeliki, Ntanasis-Stathopoulos Ioannis, Kokkali Nikoletta-Aikaterini, Papanota Aristea-Maria, Migkou Magdalini, Malandrakis Panagiotis, Spiliopoulou Vasiliki, Liontos Michalis, Zagouri Flora, Kaparelou Maria, Papatheodoridi Alkistis, Terpos Evangelos, Kastritis Efstathios, Dimopoulos Meletios-Athanasios, Gavriatopoulou Maria
机构信息
Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Department of Medicine, Korea University, Seoul, South Korea.
出版信息
Br J Haematol. 2025 Jun;206(6):1849-1852. doi: 10.1111/bjh.20143. Epub 2025 May 12.
Abstract
摘要
相似文献
1
Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal protein.实体瘤患者意义未明的单克隆丙种球蛋白病：免疫检查点抑制剂对单克隆蛋白的影响
Br J Haematol. 2025 Jun;206(6):1849-1852. doi: 10.1111/bjh.20143. Epub 2025 May 12.
2
Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).意义未明的单克隆丙种球蛋白病（MGUS）意义未明的单克隆丙种球蛋白病（MGUS）。
Klin Onkol. 2018 Summer;31(4):270-276. doi: 10.14735/amko2018270.
3
[Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].2014年意义未明的单克隆丙种球蛋白病及无症状多发性骨髓瘤
Vnitr Lek. 2014 Oct;60(10):861-79.
4
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.意义未明单克隆丙种球蛋白血症和多发性骨髓瘤的淋巴细胞亚群和炎症细胞因子。
Int J Mol Sci. 2019 Jun 10;20(11):2822. doi: 10.3390/ijms20112822.
5
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.多发性骨髓瘤与意义未明的单克隆丙种球蛋白病对相同抗骨髓瘤治疗的反应比较：一项回顾性队列研究
Lancet Haematol. 2017 Dec;4(12):e584-e594. doi: 10.1016/S2352-3026(17)30209-0. Epub 2017 Nov 13.
6
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.意义未明的单克隆丙种球蛋白病：全面综述
Clin Lymphoma Myeloma Leuk. 2023 May;23(5):e195-e212. doi: 10.1016/j.clml.2023.02.004. Epub 2023 Feb 23.
7
Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.存在意义未明的单克隆丙种球蛋白病的患者实体器官移植的肿瘤性和非肿瘤性并发症
Clin Transplant. 2015 Sep;29(9):851-7. doi: 10.1111/ctr.12595. Epub 2015 Aug 20.
8
[Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].意义未明的单克隆丙种球蛋白病及其向骨髓瘤的演变：153例患者的经验
Semergen. 2021 Oct;47(7):441-447. doi: 10.1016/j.semerg.2021.05.011. Epub 2021 Sep 1.
9
Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.MGUS 诊断后血清单克隆蛋白速度与意义未明单克隆丙种球蛋白病进展为多发性骨髓瘤。
Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2055-2061. doi: 10.1158/1055-9965.EPI-19-0132. Epub 2019 Sep 9.
10
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.意义未明的单克隆丙种球蛋白病和冒烟型多发性骨髓瘤
Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22.
本文引用的文献
1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
2
From MGUS to multiple myeloma: Unraveling the unknown of precursor states.从意义未明的单克隆丙种球蛋白血症到多发性骨髓瘤：揭开前体状态的未知面纱。
Blood Rev. 2024 Nov;68:101242. doi: 10.1016/j.blre.2024.101242. Epub 2024 Oct 6.
3
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.靶向免疫疗法：利用免疫系统对抗多发性骨髓瘤。
Cell Death Discov. 2024 Jan 27;10(1):55. doi: 10.1038/s41420-024-01818-6.
4
Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden.既往癌症与意义未明的单克隆丙种球蛋白血症风险：冰岛和瑞典的一项基于人群的研究。
Haematologica. 2024 Jul 1;109(7):2250-2255. doi: 10.3324/haematol.2023.284365.
5
Immune checkpoint inhibitors for multiple myeloma immunotherapy.用于多发性骨髓瘤免疫治疗的免疫检查点抑制剂
Exp Hematol Oncol. 2023 Nov 28;12(1):99. doi: 10.1186/s40164-023-00456-5.
6
Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises.多发性骨髓瘤中的检查点抑制剂：诱人的潜力与未实现的承诺
Cancers (Basel). 2021 Dec 27;14(1):113. doi: 10.3390/cancers14010113.
7
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.度伐利尤单抗联合达雷妥尤单抗治疗达雷妥尤单抗难治性多发性骨髓瘤患者的疗效和安全性
Cancers (Basel). 2021 May 18;13(10):2452. doi: 10.3390/cancers13102452.
8
Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.自体造血干细胞移植后伊匹单抗联合纳武利尤单抗巩固治疗的安全性和疗效。
Transplant Cell Ther. 2021 May;27(5):391-403. doi: 10.1016/j.jtct.2020.12.026. Epub 2020 Dec 30.
9
Immune checkpoint inhibitors in multiple myeloma: A review of the literature.多发性骨髓瘤中的免疫检查点抑制剂：文献综述
Pathol Res Pract. 2020 Oct;216(10):153114. doi: 10.1016/j.prp.2020.153114. Epub 2020 Jul 13.
10
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.PD-L1-PD-1通路在多发性骨髓瘤病理生理学中的作用
Cancers (Basel). 2020 Apr 10;12(4):924. doi: 10.3390/cancers12040924.
Zotero 插件